Antibody–drug conjugates (ADCs) derived from interchain cysteine cross-linking demonstrate improved homogeneity and other pharmacological properties over …

…, D Houser, K Venstrom, Z Levashova… - Molecular …, 2015 - ACS Publications
Conventional antibody–drug conjugates (ADCs) are heterogeneous mixtures of chemically
distinct molecules that vary in both drugs/antibody (DAR) and conjugation sites. Suboptimal …

Antitumor activity of an anti‐CD 98 antibody

…, JM Cantor, B Cairns, Z Levashova… - … journal of cancer, 2015 - Wiley Online Library
CD98 is expressed on several tissue types and specifically upregulated on fast‐cycling cells
undergoing clonal expansion. Various solid (eg., nonsmall cell lung carcinoma) as well as …

In vivo tumor angiogenesis imaging with site-specific labeled 99mTc-HYNIC-VEGF

FG Blankenberg, MV Backer, Z Levashova… - European journal of …, 2006 - Springer
Purpose We recently developed a cysteine-containing peptide tag (C-tag) that allows for site-specific
modification of C-tag-containing fusion proteins with a bifunctional chelator, HYNIC …

Improved detection of cell death in vivo with annexin V radiolabeled by site-specific methods

JF Tait, C Smith, Z Levashova, B Patel… - Journal of Nuclear …, 2006 - Soc Nuclear Med
Labeled annexin V is widely used to detect cell death in vitro and in vivo. Nearly all studies
have been done with annexin V derivatized via amine-directed bifunctional agents; it was …

Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression

…, FG Blankenberg, Z Levashova… - … , and vascular biology, 2009 - Am Heart Assoc
Objective— Mural inflammation and neovascularization are characteristic pathological features
of abdominal aortic aneurysm (AAA) disease. Vascular endothelial growth factor receptor …

Treating tissue factor–positive cancers with antibody–drug conjugates that do not affect blood clotting

…, AD Avery, R Dorfman, S Guelman, Z Levashova… - Molecular Cancer …, 2018 - AACR
The primary function of tissue factor (TF) resides in the vasculature as a cofactor of blood
clotting; however, multiple solid tumors aberrantly express this transmembrane receptor on the …

[HTML][HTML] CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma

GM Hayes, B Cairns, Z Levashova… - American Journal of …, 2015 - ncbi.nlm.nih.gov
Soft tissue sarcoma (STS) is a heterogenous tumor arising from the embryonic mesoderm
represented by approximately 50 histological subtypes. Effective therapeutic intervention is …

Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study

FG Blankenberg, Z Levashova, SK Sarkar… - Translational …, 2010 - Elsevier
Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) drive angiogenesis,
and several VEGFR inhibitors are already approved for use as single agents or in …

Direct site-specific labeling of the Cys-tag moiety in scVEGF with technetium 99m

Z Levashova, M Backer, JM Backer… - Bioconjugate …, 2008 - ACS Publications
Angiogenesis is a fundamental feature of tumor development, and therefore, the tracers for
molecular imaging of specific angiogenic biomarkers are expected to be useful for diagnostics…

Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors

Z Levashova, M Backer, CV Hamby… - Journal of Nuclear …, 2010 - Soc Nuclear Med
Several drugs targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs)
are approved for cancer treatment. However, these drugs induce relatively modest and …